- Artificial Intelligence for Cancer Detection | iCAD
Explore how radiologists and patients benefit from iCAD's ProFound AI solutions for early breast cancer detection, density, and risk assessment
- Press Releases - iCAD
Los Angeles, CA – July 17, 2025, RadNet, Inc (NASDAQ: RDNT) (“RadNet”), a national leader in providing high-quality, cost-effective diagnostic imaging services and digital health solutions, announced today that it has completed the acquisition of iCAD, Inc (NASDAQ: ICAD) (“iCAD”), a global leader in AI-powered breast health solutions
- ProFound AI Breast Cancer Health Suite | iCAD
Explore iCAD's ProFound AI solutions – find breast cancer earlier, with unmatched accuracy, 2x clinical performance, and personalized density and risk assessment
- Our Health AI Medical Company Overview | iCAD
The iCAD mission is to create a world where cancer can’t hide, using innovative artificial intelligence solutions Learn about our health AI medical company
- News and Events for AI Powered Cancer Detection | iCAD
Explore iCAD's webinars, press releases, and media coverage All focused on how ProFound AI is helping radiologists and patients through early breast cancer detection
- ProFound AI - iCAD
iCAD, Inc All rights reserved iCAD, the iCAD logo, PowerLook and ProFound are registered trademarks of iCAD, Inc Reproduction of any of the material contained herein in any format or media without the express written permission of iCAD, Inc is prohibited
- The Science of Using AI to Detect Breast Cancer | iCAD
Radiologists using iCAD’s best-in-class AI-powered solutions are achieving remarkable outcomes Learn about the science behind the ProFound solutions to detect breast cancer
- RadNet’s Wholly-Owned Subsidiary, DeepHealth, Completes Acquisition of iCAD
iCAD’s extensive AI portfolio—including breast cancer detection, risk evaluation, breast density, and breast arterial calcification assessment—is deployed in more than 50 countries
|